首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   156783篇
  免费   32775篇
  国内免费   2431篇
耳鼻咽喉   5256篇
儿科学   5787篇
妇产科学   2514篇
基础医学   4261篇
口腔科学   1573篇
临床医学   27081篇
内科学   48852篇
皮肤病学   7549篇
神经病学   15276篇
特种医学   6619篇
外科学   42075篇
综合类   253篇
现状与发展   73篇
一般理论   1篇
预防医学   7174篇
眼科学   3435篇
药学   1566篇
中国医学   48篇
肿瘤学   12596篇
  2024年   686篇
  2023年   4811篇
  2022年   1280篇
  2021年   3209篇
  2020年   6114篇
  2019年   2248篇
  2018年   7503篇
  2017年   7449篇
  2016年   8531篇
  2015年   8515篇
  2014年   15651篇
  2013年   15778篇
  2012年   5798篇
  2011年   5919篇
  2010年   10595篇
  2009年   14469篇
  2008年   6177篇
  2007年   4393篇
  2006年   6895篇
  2005年   4241篇
  2004年   3489篇
  2003年   2489篇
  2002年   2508篇
  2001年   3937篇
  2000年   3122篇
  1999年   3319篇
  1998年   3755篇
  1997年   3546篇
  1996年   3440篇
  1995年   3294篇
  1994年   2012篇
  1993年   1651篇
  1992年   1472篇
  1991年   1490篇
  1990年   1154篇
  1989年   1279篇
  1988年   1107篇
  1987年   925篇
  1986年   950篇
  1985年   787篇
  1984年   595篇
  1983年   548篇
  1982年   548篇
  1981年   428篇
  1980年   377篇
  1979年   351篇
  1978年   364篇
  1977年   419篇
  1975年   300篇
  1972年   312篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
141.
142.
143.
This review discusses treatment options for men with premature ejaculation (PE), a common sexual dysfunction characterized by short ejaculatory latency, decreased sexual satisfaction, and distress. For a number of reasons, including embarrassment and the belief that PE is a normal part of aging, that it has no effective treatment, or that it will resolve itself, few men with PE seek treatment. Although several treatment options exist (eg, behavioral, cognitive, and sex therapy methods; desensitizing drugs; off-label use of antidepressants, phosphodiesterase type 5 inhibitors, or à-blockers), the majority of men with PE are not satisfied with their results. New pharmacologic drugs develped specifically for the treatment of PE are undergoing evaluation in clinical trials. For example, recent clinical research studies have revealed on-demand administration of one such drug, dapoxetine, which achieved significant improvements in ejaculatory latency, control over ejaculation, and satisfaction with sexual intercourse. In addition, partners of men who received dapoxetine likewise reported improved satisfaction with sexual intercourse. Future studies may reveal that integration of pharmacologic drugs with psychologic and/or behavioral therapy techniques may be the optimal approach to the management of PE. PE is a treatable condition, and new drugs in development may provide benefits over those available.  相似文献   
144.
145.
146.
Editorial     
  相似文献   
147.
148.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility.  相似文献   
149.
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels.  相似文献   
150.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号